<p>Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant</p>-Reference-Cited by-同舟云学术

Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant

Published:2020-11 Issue: Volume:Volume 13 Page:11471-11484
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Li Qing,Mu Juan^ORCID,Yuan Jijun,Yang Zhenxing,Wang Jia^ORCID,Deng Qi

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Reference34 articles.

1. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT

2. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation

3. A multicentre UK study of GVHD following DLI: Rates of GVHD are high but mortality from GVHD is infrequent

4. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

5. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies;Cancers;2022-09-14

2. Building a CAR-T cell therapy program in a pediatric hemato-oncology department. Preliminary data;Anales de Pediatría (English Edition);2022-08

3. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation;International Journal of Hematology;2022-06-23

4. Resultados preliminares tras la instauración del programa con medicamentos CAR-T en leucemia aguda linfoblástica en un centro pediátrico;Anales de Pediatría;2021-12

5. An owner's manual for CD19 “CAR”-T cell therapy in managing pediatric and young adult B-cell acute lymphoblastic leukemia;Blood Reviews;2021-11